[Results of prophylactic intra-arterial infusion chemotherapy after hepatic resection in colorectal metastases].
Fourteen colorectal cancer patients with metastatic liver metastases who received prophylactic intra-arterial infusion chemotherapy (IAIC) after curative resection for liver metastases at the National Cancer Center Hospital from May 1987 to December 1989 were reviewed. 5-fluorouracil (5-FU) (15 mg/kg) and mitomycin C (MMC) (0.1 mg/kg) were infused through implantable ports weekly or every two weeks. Five patients (35.7%) developed recurrent tumors in the residual liver during 3-12 months after hepatic resection. The se five patients had more than two metastatic lesions in the liver at hepatectomy. Four patients with solitary metastatic tumor had no recurrent liver diseases. The most serious complication was sclerosing cholangitis which occurred in two patients (14%) in this series. Both cases needed drainage PTCD, but one of them died from gastro-intestinal bleeding due to hepatic failure and the other from pneumonia. These two cases showed no recurrent liver cancers.
Kawano
N
N
Colorectal Unit, National Cancer Center Hospital.
Sugihara
K
K
Moriya
Y
Y
Houjo
K
K
D000284:Administration, Oral; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D015179:Colorectal Neoplasms / Q000473:pathology; D005472:Fluorouracil / Q000008:administration & dosage; D006498:Hepatectomy; D006801:Humans; D015918:Infusion Pumps, Implantable; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000517:prevention & control* / Q000556:secondary / Q000601:surgery; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D011182:Postoperative Care; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage
D008937:Mitomycins; D005641:Tegafur; D016685:Mitomycin; D014498:Uracil; D005472:Fluorouracil